Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 5, 2002, Pages 398-402

  Shepard, Dale R ^a   Mani, Sridhar ^a   Kastrissios, Helen ^b   Learned Coughlin, Susan ^c   Smith, Deborah ^c   Ertel, Phillip ^c   Magnum, Steve ^c   Janisch, Linda ^a   Fleming, Gini F ^a   Schilsky, Richard L ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

5 Fluorouracil; Eniluracil; Food drug interaction; Pharmacokinetic analysis

Indexed keywords

5 ETHYNYLURACIL; FLUOROURACIL;

ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIET; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; ENDOMETRIUM CANCER; FEMALE; FOOD; FOOD DRUG INTERACTION; GALLBLADDER CANCER; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MEAL; OVARY CANCER; POPULATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; STOMACH CANCER; TIME;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXIDOREDUCTASES; POPULATION; THERAPEUTIC EQUIVALENCY; URACIL;

EID: 0036232578     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0431-9     Document Type: Article

References (33)

1. Fluoronated pyrimidines, a new class of tumour-inhibitory compounds
2. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase
3. 5-Flurouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity
4. 5-Fluorouracil incorporation in DNA of human breast carcinoma cells
5. Pharmacokinetics of 5-FU administered orally, by rapid iv infusion, and by slow infusion
6. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer
7. Relationship between fluorouracil systemic exposure and tumor response and patient survival
8. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-flurouracil by protracted continuous infusion
9. Familial defi-ciency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
10. Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency
11. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
12. Enzymes of uracil catabolism in normal and neoplastic human tissues
13. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
14. Mechanism-based inactivation of dihydropyrimidine dehydro-genase by 5-ethynyluracil
15. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
16. Phase I clinical and pharmacological study of eniluracil plus fluorouracil in patients with advanced cancer
17. 5-Ethynyluracil (776C85): A potent modulator of the pharmaco-kinetics and antitumor eBcacy of 5-fluorouracil
18. Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation
19. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil eBcacy and therapeutic index in rats bearing advanced colorectal carcinoma
20. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors
21. Pharmacokinetic, oral bioavail-ability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
22. Bioequivalence: Individual and population compartmental modeling compared to the noncompartmental approach
23. Application of NONMEM method to evaluation of the bioavailability of drug products
24. Inhibition of dihydropyrimidine dehy-drogenase by alpha-interferon: Experimental data on human tumor cell lines
25. Lack of effect of interferon α2a upon fluorouracil pharmacokinetics
26. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
27. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers
28. Lamivudine/zidovudine as a combined formulation tablet: Bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption
29. PhRMA perspective on population and individual bioequivalence
30. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)
31. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies